Tiago V Augusto1, Cristina Amaral1, Yuanzhong Wang2, Shiuan Chen2, Cristina F Almeida1, Natércia Teixeira3, Georgina Correia-da-Silva4. 1. Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, UCIBIO.REQUIMTE, University of Porto, Rua Jorge Viterbo Ferreira no. 228, 4050-313, Porto, Portugal. 2. Department of Cancer Biology, Beckman Research Institute of the City of Hope, Duarte, CA, USA. 3. Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, UCIBIO.REQUIMTE, University of Porto, Rua Jorge Viterbo Ferreira no. 228, 4050-313, Porto, Portugal. natercia@ff.up.pt. 4. Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, UCIBIO.REQUIMTE, University of Porto, Rua Jorge Viterbo Ferreira no. 228, 4050-313, Porto, Portugal. george@ff.up.pt.
Abstract
INTRODUCTION: Breast cancer is the leading cause of cancer death in women. The aromatase inhibitors (AIs), Anastrozole (Ana), Letrozole (Let), and Exemestane (Exe) are a first-line treatment option for estrogen receptor-positive (ER+) breast tumors, in postmenopausal women. Nevertheless, the development of acquired resistance to this therapy is a major drawback. The involvement of PI3K in resistance, through activation of the PI3K/AKT/mTOR survival pathway or through a cytoprotective autophagic process, is widely described. MATERIALS AND METHODS: The involvement of autophagy in response to Ana and Let treatments and the effects of the combination of BYL-719, a PI3K inhibitor, with AIs were explored in AI-resistant breast cancer cell lines (LTEDaro, AnaR, LetR, and ExeR). RESULTS: We demonstrate that Ana and Let treatments do not promote autophagy in resistant breast cancer cells, contrary to Exe. Moreover, the combinations of BYL-719 with AIs decrease cell viability by different mechanisms by nonsteroidal vs. steroidal AIs. The combination of BYL-719 with Ana or Let induced cell cycle arrest while the combination with Exe promoted cell cycle arrest and apoptosis. In addition, BYL-719 decreased AnaR, LetR, and ExeR cell viability in a dose- and time-dependent manner, being more effective in the ExeR cell line. This decrease was further exacerbated by ICI 182,780. CONCLUSION: These results corroborate the lack of cross-resistance between AIs verified in the clinic, excluding autophagy as a mechanism of resistance to Ana or Let and supporting the ongoing clinical trials combining BYL-719 with AIs.
INTRODUCTION: Breast cancer is the leading cause of cancer death in women. The aromatase inhibitors (AIs), Anastrozole (Ana), Letrozole (Let), and Exemestane (Exe) are a first-line treatment option for estrogen receptor-positive (ER+) breast tumors, in postmenopausal women. Nevertheless, the development of acquired resistance to this therapy is a major drawback. The involvement of PI3K in resistance, through activation of the PI3K/AKT/mTOR survival pathway or through a cytoprotective autophagic process, is widely described. MATERIALS AND METHODS: The involvement of autophagy in response to Ana and Let treatments and the effects of the combination of BYL-719, a PI3K inhibitor, with AIs were explored in AI-resistant breast cancer cell lines (LTEDaro, AnaR, LetR, and ExeR). RESULTS: We demonstrate that Ana and Let treatments do not promote autophagy in resistant breast cancer cells, contrary to Exe. Moreover, the combinations of BYL-719 with AIs decrease cell viability by different mechanisms by nonsteroidal vs. steroidal AIs. The combination of BYL-719 with Ana or Let induced cell cycle arrest while the combination with Exe promoted cell cycle arrest and apoptosis. In addition, BYL-719 decreased AnaR, LetR, and ExeR cell viability in a dose- and time-dependent manner, being more effective in the ExeR cell line. This decrease was further exacerbated by ICI 182,780. CONCLUSION: These results corroborate the lack of cross-resistance between AIs verified in the clinic, excluding autophagy as a mechanism of resistance to Ana or Let and supporting the ongoing clinical trials combining BYL-719 with AIs.
Authors: Todd W Miller; Bryan T Hennessy; Ana M González-Angulo; Emily M Fox; Gordon B Mills; Heidi Chen; Catherine Higham; Carlos García-Echeverría; Yu Shyr; Carlos L Arteaga Journal: J Clin Invest Date: 2010-06-07 Impact factor: 14.808
Authors: F Cardoso; S Kyriakides; S Ohno; F Penault-Llorca; P Poortmans; I T Rubio; S Zackrisson; E Senkus Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: William F Anderson; Nilanjan Chatterjee; William B Ershler; Otis W Brawley Journal: Breast Cancer Res Treat Date: 2002-11 Impact factor: 4.872
Authors: Miriam Martini; Maria Chiara De Santis; Laura Braccini; Federico Gulluni; Emilio Hirsch Journal: Ann Med Date: 2014-06-05 Impact factor: 4.709
Authors: F Cardoso; S Paluch-Shimon; E Senkus; G Curigliano; M S Aapro; F André; C H Barrios; J Bergh; G S Bhattacharyya; L Biganzoli; F Boyle; M-J Cardoso; L A Carey; J Cortés; N S El Saghir; M Elzayat; A Eniu; L Fallowfield; P A Francis; K Gelmon; J Gligorov; R Haidinger; N Harbeck; X Hu; B Kaufman; R Kaur; B E Kiely; S-B Kim; N U Lin; S A Mertz; S Neciosup; B V Offersen; S Ohno; O Pagani; A Prat; F Penault-Llorca; H S Rugo; G W Sledge; C Thomssen; D A Vorobiof; T Wiseman; B Xu; L Norton; A Costa; E P Winer Journal: Ann Oncol Date: 2020-09-23 Impact factor: 32.976